SCHEMBL542497

SCHEMBL542497

O=C1NC(=O)C2(CCCC2)N1

nearest known ligand 0.95

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 16/20 0.47
CRBN Q96SW2 1/20 0.43
PDE7B Q9NP56 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL551553 0.97 PDE7A (0.50) PDE7ACRBNPDE7B
SCHEMBL11491220 0.97 PDE7A (0.50) PDE7ACRBNPDE7B
SCHEMBL351324 0.97 PDE7A (0.50) PDE7ACRBNPDE7B
SCHEMBL11870539 0.97 PDE7A (0.50) PDE7ACRBNPDE7B
SCHEMBL22422289 0.97 PDE7A (0.50) PDE7ACRBNPDE7B
SCHEMBL630549 0.95 CRBN (0.43) PDE7ACRBNPDE7B
SCHEMBL8775591 0.89
SCHEMBL23039345 0.84 PDE7A (0.41) PDE7ACRBNPDE7B
SCHEMBL31721361 0.83 CRBN (0.40) PDE7ACRBN
SCHEMBL23651601 0.83 PDE7A (0.38) PDE7ACRBNPDE7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822516-B2 Process for the preparation of iodides TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2014-09-02 US claimed
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2013-06-27 US claimed
WO-2011154953-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2011-12-15 WO claimed
EP-1042315-B1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE CO CHEM PHARM FAB (DE) 2004-04-14 EP claimed
EP-1042315-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS Klinge Pharma GmbH (DE) 2000-10-11 EP claimed
WO-1999031087-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE PHARMA GMBH (DE) 1999-06-24 WO claimed
US-5338859-A Reacting a hydantoin with a calcium base; crystallization; precipitation; separation HOECHST CELANESE CORPORATION (US) 1994-08-16 US claimed
US-4436910-A SAPONIFICATION DEGUSSA AKTIENGESELLSCHAFT (DE) 1984-03-13 US claimed
US-4320135-A HORMONE INHIBITORS, ANTIDIABETIC AGENTS, TREATMENT OF MICROANGIOPATHY SANDOZ, INC. (US) 1982-03-16 US claimed
US-12637433-B2 Histone deacetylase inhibitors THE UNIVERSITY OF QUEENSLAND (AU) 2026-05-26 US disclosed
WO-2025230799-A2 CYCLOALKYL- AND PIPERIDINYL-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS SEPTERNA, INC. (US) 2025-11-06 WO disclosed
EP-3947365-B1 SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF BIONOMICS LTD (AU) 2025-10-01 EP disclosed
EP-4613731-A1 HALOETHER, METHOD FOR PRODUCING SAME, VINYL ETHER, AND METHOD FOR PRODUCING SAME DAIKIN INDUSTRIES, LTD. (JP) 2025-09-10 EP disclosed
US-20250228865-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME SANOFI US SERVICES INC. (US) 2025-07-17 US disclosed
US-4227005-A (B-HYDROXYETHYL)-5,5-DIMETHYLHYDANTOIN CIBA-GEIGY AG (CH) 1980-10-07 US disclosed
US-4189587-A CORROSION RESISTANCE CIBA-GEIGY CORPORATION (US) 1980-02-19 US disclosed
US-4161594-A DERIVATIVES OF BARBITURIC ACID, HYDANTOIN, AND DIHYDROURACIL, POLYMER INTERMEDIATES CIBA-GEIGY AG (CH) 1979-07-17 US disclosed
US-4060525-A DIGLYCIDYL COMPOUND INTERMEDIATES CIBA-GEIGY AG (CH) 1977-11-29 US disclosed
US-3975397-A STORAGE STORAGE STABLE, DIMENSIONAL STABILITY, MECHANICAL STRENGTH CIBA-GEIGY CORPORATION (US) 1976-08-17 US disclosed
US-3948916-A HYDANTOINS OR URACILS, POLYEPOXIDES CIBA-GEIGY AG (CH) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637433-B2 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC3 PDE7A 555/4885CRBN 3060/4885PDE7B 1630/4885
US-20250228865-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME UPF1, NUDT21, RNGTT PDE7A 2037/4885CRBN 1442/4885PDE7B 1210/4885
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES NISCH, TPO, HDHD5 PDE7A 1691/4885CRBN 1229/4885PDE7B 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.